Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck Snaps Up Protiva Technology, Ending Legal Dispute

This article was originally published in The Pink Sheet Daily

Executive Summary

Licensing deal removes a preliminary injunction against Sirna RNAi research that Merck also owns.

You may also be interested in...

Alnylam Signs Billion Dollar RNAi Deal With Roche

Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.

Pfizer Boosts RNAi Interest With Sigma-Aldrich Licensing Agreement

Deal comes on the heels of September agreement for potential RNAi therapy for macular degeneration.

Yes, Sirna: Merck Inks $1.1 Bil. Deal For RNAi Firm

Merck continues acquisition spurt with purchase of San Francisco biotech.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts